Maria Pena, MD
Endocrinology, Diabetes & Metabolism · Rego Park, NYNPI 1487815361
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $218,783 of the $238,924 with a category attached, or 91.6%. Novo Nordisk accounts for 85.3% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2022 at $63,967 and has fallen 67.7% since, to $20,670 in 2025. Among endocrinology, diabetes & metabolism clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 336 payments — averaging $711.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$204K
- AstraZeneca$33K
- Lilly USA, LLC$355
- Abbott$314
- Mannkind Corporation$309
- Novartis$193
- plus $1K from 26 others
What the payments were for
- Consulting fees$3,7502%
- Speaking & faculty fees$218,78392%
- Travel & lodging$6,7973%
- Food & beverage$9,4704%
- Education$650%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 200 | $203,749 |
| AstraZeneca(2 entities) | 50 | $32,661 |
| Lilly USA, LLC | 10 | $355 |
| Abbott | 4 | $314 |
| Mannkind Corporation | 3 | $309 |
| Novartis | 11 | $193 |
| Boehringer Ingelheim | 4 | $192 |
| Amgen | 7 | $129 |
| Madrigal Pharmaceuticals | 5 | $114 |
| AbbVie | 5 | $99 |
| Amneal Pharmaceuticals LLC | 3 | $81 |
| OPKO Pharmaceuticals, LLC | 4 | $71 |
| Corcept Therapeutics | 2 | $63 |
| Ascensia Diabetes Care US Inc. | 2 | $59 |
| Kyowa Kirin, Inc. | 2 | $54 |
| Sanofi-aventis U.S. LLC | 3 | $53 |
| Currax Pharmaceuticals LLC | 3 | $46 |
| Medtronic | 2 | $41 |
| Xeris Pharmaceuticals, Inc. | 2 | $40 |
| Integra Lifesciences Corporation | 1 | $37 |
| Rhythm Pharmaceuticals, Inc. | 2 | $36 |
| Cvrx, Inc. | 1 | $35 |
| BETA Bionics, Inc. | 1 | $25 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $24 |
| Chiesi USA, Inc. | 1 | $22 |
| Insulet Corporation | 1 | $21 |
| Lexicon Pharmaceuticals, Inc. | 1 | $20 |
| Almatica Pharma LLC | 1 | $20 |
| Recordati_rare_diseases_inc. | 1 | $17 |
| Eisai Inc. | 1 | $17 |
| Philips North America LLC | 1 | $17 |
| Cequr Corporation | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$91,953
- RYBELSUS$60,097
- FARXIGA$31,956
- Wegovy$20,001
- Tresiba$8,459
- Xultophy 100/3.6$1,855
- AFREZZA$249
- Mitra Clip system$141
- FREESTYLE LIBRE 3$122
- JARDIANCE$122
- Levemir$120
- NovoLog$120
- NovoLog Mix 70/30$120
- ZEPBOUND$118
How this compares
$238,924 in reported general payments places this provider in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 229 | $394,233 |
| MounjaroTirzepatide | 188 | $290,116 |
| JardianceEmpagliflozin | 146 | $211,909 |
| TrulicityDulaglutide | 123 | $209,979 |
| RybelsusSemaglutide | 25 | $62,758 |
| FarxigaDapagliflozin Propanediol | 42 | $54,955 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 26 | $43,447 |
| WegovySemaglutide | 13 | $29,059 |
| TradjentaLinagliptin | 18 | $18,739 |
| JanuviaSitagliptin Phosphate | 18 | $18,304 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $17,552 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $14,095 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 22 | $9,264 |
| Testosterone | 15 | $4,875 |
| SynthroidLevothyroxine Sodium | 41 | $3,421 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $355 | $500,095311 claims |
| Novo NordiskOzempic, Rybelsus, Wegovy | $203,749 | $486,050267 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $192 | $274,094190 claims |
| AstraZenecaFarxiga | $32,661 | $54,95542 claims |
| AbbVieSynthroid | $99 | $3,42141 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $81 | $1,62298 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in Rego Park
- Stella IlyayevaRego Park$219K
- Robert BuschAlbany$2.7M
- Michael ShanikSmithtown$1.2M
- Ajay ChaudhuriBuffalo$888K
- Vinay KapoorManhasset$820K
- John BilezikianNew York$809K
- Barbara HirschManhasset$746K
- Martin GrajowerBronx$713K
- Anastasios ManessisNew York$656K
- Jonas LeibowitzYonkers$613K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.